Hypoallergenic high-dose immunotherapy proves effective and safe in a multicentre surveillance study

Background: The safety and efficacy of subcutaneous immunotherapy (SCIT) with the high-dose hypoallergenic preparations Allergovit® have been well documented in several randomised clinical trials. The following study aimed to confirm these results in daily practice.